Recent major improvement in long-term survival of younger patients with multiple myeloma
Recent major improvement in long-term survival of younger patients with multiple myeloma
复制标题
DOI：
10.1182/blood-2007-08-104984
复制
发表时间：
2008-03-01
期刊：
影响因子：
20.3
通讯作者：
Pulte, Dianne
中科院分区：
文献类型：
--
作者：
Brenner, Hermann;Gondos, Adam;Pulte, Dianne
过去，大多数多发性骨髓瘤(MM)患者在确诊后5至10年内死亡。在过去的十年中，已经推出了几种新的治疗措施，包括自体干细胞移植、沙利度胺、来那度胺和硼替佐米。我们从1973年至2004年监测、流行病学和最终结果(SEER)计划的数据库中估计了1990-1992年至2002-2004年期间美国多发性骨髓瘤患者特定年龄的5年和10年相对生存率的趋势。周期分析技术被用来显示最新的发展。总体而言，5年相对生存率从28.8%上升到34.7%(P
In the past, most patients with multiple myeloma (MM) died within 5 to 10 years after diagnosis. Within the past decade, several new therapeutic interventions have been introduced, including autologous stem-cell transplantation, thalidomide, lenalidomide, and bortezomib. We estimated trends in age-specific 5- and 10-year relative survival of patients with MM in the United States from 1990-1992 to 2002-2004 from the 1973-2004 database of the Surveillance, Epidemiology, and End Results (SEER) Program. Techniques of period analysis were used to show most recent developments. Overall, 5-year relative survival increased from 28.8% to 34.7% (P